Short answer
Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on February 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Larimar priced public offering of 20M shares at $5.00/share; underwriters exercised full 3M share overallotment on Feb 26, 2026.
Larimar Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Larimar priced public offering of 20M shares at $5.00/share; underwriters exercised full 3M share overallotment on Feb 26, 2026
- Total shares sold: 23M; net proceeds ~$107.6M after underwriting discounts and estimated expenses
- Significant dilution event: 23M new shares issued; existing shareholders should assess impact on ownership percentage
- J.P. Morgan and Guggenheim Securities acted as joint bookrunning managers; closing expected Feb 27, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Larimar Therapeutics, Inc. 8-K filings
Get the next LRMR 8-K as it lands
Follow LRMR for push alerts, or ask the research agent what this filing means.